News about "GSK"

GSK Partners with Sino Biopharmaceutical to Accelerate Hepatitis B Therapy Launch in China

GSK and Sino Biopharmaceutical’s CTTQ have partnered to accelerate the launch of bepirovirsen in China, aiming to expand access to a potential first-in-class chronic hepatitis B therapy with functional cure potential.

GSK | 12/05/2026 | By News Bureau

Onco-Innovations Subsidiary Partners with GSK on Real-World Oncology Data Research

Inka Health and GSK will collaborate to develop real-world data methodologies aimed at improving the applicability of oncology clinical trial findings across diverse patient populations and healthcare settings.

GSK | 07/05/2026 | By News Bureau

GSK Acquires 100 Percent Equity of 35Pharma for USD 950 Million

GSK completes acquisition of 35Pharma, adding HS235, a potential best-in-class therapy for Pulmonary Hypertension.

GSK | 16/04/2026 | By News Bureau

GSK Reports Positive Data for B7-H4 ADC in Gynecological Cancers

GSK reports positive BEHOLD-1 data for B7-H4 ADC mocertatug rezetecan, showing strong response rates in ovarian and endometrial cancers, with Phase 3 trials planned.

GSK | 14/04/2026 | By News Bureau |  105

NMPA Nod for GSK's Exdensur Boosts Biologics Manufacturing Momentum

GSK plc has received approval from China’s National Medical Products Administration (NMPA) for Exdensur (depemokimab) as an add-on maintenance therapy for severe asthma with an eosinophilic phenotype in patients aged 12 years and above.

GSK | 31/03/2026 | By Darshana

US FDA Approves GSK's AREXVY for At-Risk Adults Aged 18 to 49 Years

The US FDA has approved GSK’s RSV vaccine, AREXVY, for adults aged 18–49 who are at increased risk of severe RSV infection, expanding protection to an estimated 21 million at-risk individuals in this age group.

GSK | 16/03/2026 | By News Bureau |  102

GSK completes acquisition of RAPT Therapeutics

GSK has completed the acquisition of RAPT Therapeutics, adding ozureprubart, a long-acting anti-IgE monoclonal antibody, to its pipeline. The candidate is currently in phase-II(b) development for prophylactic protection against food allergens, strengthening GSK’s immunology portfolio.

GSK | 05/03/2026 | By Akanki |  107

GSK's Linerixibat Granted Priority Review in China for Cholestatic Pruritus in PBC

China’s drug regulator has accepted GSK’s linerixibat for priority review to treat cholestatic pruritus in primary biliary cholangitis, supported by Phase III data showing significant and sustained itch relief.

GSK | 27/02/2026 | By News Bureau |  171

Japan's MHLW accepts GSK's Bepirovisen for Review to Treat Chronic Hepatitis B

Japan’s health ministry has accepted GSK’s new drug application for investigational antisense therapy bepirovirsen, after Phase III trials showed significantly higher functional cure rates in chronic hepatitis B patients.

GSK | 27/02/2026 | By News Bureau |  520

Frontier Biotechnologies Inc. Signs USD 1 Billion siRNA Licensing Deal with GSK

Frontier Biotech has granted GSK exclusive global rights to two siRNA drug candidates in a deal worth up to USD 1 billion, strengthening its international expansion and immunology pipeline focus.

GSK | 25/02/2026 | By News Bureau |  222